1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

SHEZF
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.US flagOther OTC
0.47
USD
- -
- -
689.04MMarket Cap
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
SHEZF
(Other OTC)

Recent

price

0.47

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
6.23
1.95
1.38
1.18
1.53
1.81
1.8
2.28
3.86
3.71
3.94
4.34
4.88
3.71
3.6
3.73
3.58
Revenue per Share
1.96
0.49
0.49
0.25
0.26
0.46
0.32
0.16
0.47
0.85
0.76
0.16
0.5
-0.53
0.44
0.24
0.28
Basic EPS, GAAP
0.52
1
0.18
0.1
0.58
0.57
-0.01
-0.92
0.08
-0.47
-0.13
-0.14
-0.67
-0.03
1.36
1.08
-0.13
Free Cash Flow per Basic Share
0.01
0.63
0.37
0.38
0.21
0.23
0.43
0.37
0.2
0.27
0.33
0.28
0.17
0.29
0.11
0.29
0.08
Dividend per Share
3.35
1.75
1.8
1.65
1.69
1.98
2.26
2.1
2.59
3.31
3.8
3.49
3.94
3.31
3.75
3.74
3.79
Book Value per Share
12.93
6.15
6.23
6.16
5.37
4.65
4.02
4.05
2.58
3.56
6.54
5.99
6.46
6.25
6.43
6.44
6.46
Tangible Book Value per Share
618
1,276
1,281
1,280
1,280
1,268
1,254
1,247
1,247
1,247
1,353
1,467
1,468
1,467
1,467
1,467
1,468
Basic Weighted Avg Shares
3,853
2,495
1,762
1,513
1,959
2,292
2,261
2,843
4,815
4,625
5,332
6,365
7,159
5,446
5,281
5,479
5,261
Sales/Revenue/Turnover
36.12
22.9
27.89
10.01
12.31
19.63
11.78
10.36
22.47
17.93
21.13
15.15
15.68
11.75
14.06
11.61
11.35
Operating Margin (%)
11
12
17
25
39
98
162
183
223
256
304
303
308
374
331
373
- -
Depreciation Expense
1,210
622
624
317
338
580
397
197
591
1,059
1,024
241
727
-783
647
349
405
Net Income, GAAP
14.69
14.04
15.37
17.3
15.45
17.73
18.7
- -
19.08
20.64
23.06
- -
13.84
- -
13.95
14.82
13.33
Effective Tax Rate (%)
31.39
24.94
35.44
20.97
17.27
25.29
17.55
6.92
12.28
22.91
19.21
3.78
10.16
-14.38
12.25
6.38
7.7
Profit Margin (%)
7,897
7,676
7,576
7,046
6,572
5,561
4,637
2,254
938
1,003
5,516
5,978
6,814
5,618
5,922
5,198
5,359
Working Capital
- -
- -
- -
- -
1,005
1,785
2,095
1,824
2,449
2,442
3,137
2,354
2,407
1,900
1,139
338
569
LT Debt
8,024
7,914
8,045
8,068
8,353
8,793
8,089
7,999
6,276
7,472
11,689
11,523
12,409
11,988
12,202
12,080
12,212
Total Equity
25.08
6.14
5.18
1.54
2.33
3.59
1.86
- -
7.19
5.22
5.53
- -
5.35
- -
3.81
3.49
3.19
Return on Invested Capital (%)
73.69
28.22
17.96
13.81
13.43
15.32
7.96
- -
9.56
13.48
11.29
- -
8.12
- -
8.07
4.74
5.45
Return on Capital (%)
80.22
28.92
27.52
14.38
15.83
24.8
14.86
7.22
20.25
28.81
22.1
4.7
13.35
-14.73
12.49
6.36
7.31
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
2,406
2,564
2,525
LT Borrowings
1,081
980
528
LT Finance Leases
58
49
41
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,467
1,467
1,467
Market Capitalization
5,029
5,003
4,939

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
9,621
9,874
9,514
Cash, Cash Equivalents & STI
2,557
3,102
3,062
Accounts Receivable, Net
1,179
1,382
1,420
Inventories
5,394
4,953
4,670
Total Current Liabilities
3,699
3,874
4,155
Payables & Accruals
- -
- -
- -
ST Debt
2,406
2,564
2,525
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.85%
0.73%
-1%
Free Cash Flow
339.69%
-816.04%
-20.06%
Net Income, GAAP
-11.6%
-62.12%
-45.96%
Sales/Revenue/Turnover
11.37%
1.73%
3.75%
Total Cash Common Dividend
22%
25.93%
169.42%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,373
1,464
1,232
1,212
5,281
2025
1,394
1,423
1,285
- -
5,479
2026
1,331
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
- -
- -
- -
0.44
2025
0.11
- -
- -
- -
0.24
2026
0.13
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
- -
- -
- -
0.11
2025
0.02
- -
- -
- -
0.29
2026
0.01
- -
- -
- -
- -
Similar Companies
China Resources Jiangzhong Pharmaceutical Co.,Ltd (600750.SS)
Daihan Pharmaceutical Co.,Ltd. (023910.KQ)
China Traditional Chinese Medicine Holdings Co. Limited (CHIZF)
Plant-Based Investment Corp. (CWWBF)
Body and Mind Inc. (BMMJ)
Guangxi Wuzhou Zhongheng Group Co.,Ltd (600252.SS)
Business
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHEZF) manufactures and sells pharmaceutical products with a focus on the heparin industrial chain, CDMO services for large molecule biologics, and innovative drug research, development, and commercialization; its core offerings include finished dose products such as enoxaparin sodium injections (branded Inhixa, Neoparin, Prolongin), active pharmaceutical ingredients (APIs) comprising heparin sodium API, enoxaparin sodium API, and pancreatin API, alongside contract development and manufacturing organization (CDMO) services for recombinant biomacromolecules, gene therapy intermediates, and naturally derived pharmaceuticals through subsidiaries Cytovance Biologics and Scientific Protein Laboratories (SPL). Founded in 1998 and headquartered in Shenzhen, China, the company operates globally across over 50 countries and regions, including key markets in Europe, the United States, China, Turkey, Brazil, Thailand, New Zealand, Argentina, and South Africa; it maintains dual listings on the Hong Kong Stock Exchange (9989.HK) and Shenzhen Stock Exchange (002399.SZ), with subsidiaries like Techdow Pharma entities in Europe and the US, Aridis Pharmaceuticals, and OncoVent Biomedical. The company targets healthcare providers, hospitals, and biopharma clients in the anticoagulants, biologics, and oncology sectors, emphasizing vertically integrated heparin production and high-value innovative therapies. Recent developments include receipt of National Medical Products Administration approval in February 2025 for Phase I clinical trials of its in-house heparanase inhibitor H1710 injection for solid tumors, with first patient dosing in July 2025; a distribution agreement with Zhejiang Yongtai Pharmaceutical for US commercialization of Gabapentin capsules; continued advancement of fosaprepitant dimeglumine commercialization in the US via self-operated teams; market authorizations in South Africa, Argentina, Thailand, and New Zealand; European GMP certification and EMA approval for its Pingshan production base, boosting enoxaparin capacity to 550 million doses annually; and a licensing deal for Oregovomab with Orient EuroPharma via subsidiary Shenzhen OncoVent, alongside ongoing Phase III planning for AR-301 (tosatoxumab) targeting ventilator-associated pneumonia. In 2024, the company reported revenue of RMB5.26 billion with gross profit margin rising to 33.1% from 17.3%, driven by double-digit enoxaparin sales growth and CDMO expansion, alongside a shift to profitability with RMB647 million net profit attributable to shareholders; for H1 2025, revenue stood at RMB2.79 billion with enoxaparin sales up 21.6% year-over-year despite API pricing pressures.